PDCD1LG2 and hepatocellular carcinoma: The statistic results showed that the accuracy of these biomarkers (STEAP3 and PD-L2) were 63.0% and 85.0% in responsive and non-responsive HCC patients with sorafinib therapy, respectively (Fig. 9H).